Osi Pharmaceuticals, Inc.

Dow Agrosciences LLC

Mark Joseph Mulvihill

Andrew Philip Crew

Jing Wang

Douglas S Werner

Arno G Steinig

Lee Daniel Arnold

An-Hu Li

Heather Renee Coate

Bijoy Panicker

Meizhong Jin

Xin Chen

Ayako Honda

Kristen Michelle Mulvihill

Kam W Siu

Qinghua Weng

Hanqing Dong

Radoslaw Laufer

Han-Qing Dong

James David Beard

Brian Volk

Paula A R Tavares

Quinghua Weng

Andrew Kleinberg

Apoorba Bharadwaj

Anthony Innocenzo Nigro

Kenneth W Foreman

Cara Cesario

Yingchuan Sun

Tao Zhang

Michael J Wyle

Mridula Kadalbajoo

Qun-Sheng Ji

Arlindo Lucas Castelhano

Martha Jean Kelly

Dan Maarten Berger

John D Haley

Elizabeth Buck

Jonathan G Williams

James G Tarrant

Robin Wilkes

Ramesh C Gupta

Keith Hornberger

Lifu Ma

Matthew Cox

Amo G Steinig

Lydia Saroglou

James Joseph Gallagher

Karen Anderson Evans

Patricia Anne Beck

Vanessa Smith

Ti Wang

Rajaram Sangem

Melzhong Jin

Andrew-Philip Crew

Lee D Arnoldd

Paula AR Tavares

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention.

Substituted pteridinones for the treatment of cancer

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Fused bicyclic mTOR inhibitors

6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met. 

Substituted pyrrolo[2,3-b]-pyridines and -pyrazines

Methods and compositions for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound of Formula I, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by Formula I: wherein X, X, X, X, X, X, X, R, and Qare defined herein.

Combination cancer therapy

Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention. 

Substituted imidazopyr- and imidazotri-azines

Compounds of Formula I, as shown below and defined herein:  pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

Fused bicyclic kinase inhibitors

Compounds of Formula 1, as shown below and defined herein: 

7-aminofuropyridine derivatives

Fused bicyclic motor inhibitors

2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition. 

2-aminopyridine kinase inhibitors

Compounds of the formula  and pharmaceutically acceptable salts thereof, wherein X, X, X, X, X, X, X, R, and Qare defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. 

Furo[3,2-C]pyridines

Growing community of inventors

East Northport, NY, United States of America

Mark Joseph Mulvihill